A Two-Year Clinical Follow-Up Study in 80 CADASIL Subjects. Progression Patterns and Implications for Clinical Trials
|
|
- Russell Rich
- 5 years ago
- Views:
Transcription
1 A Two-Year Clinical Follow-Up Study in 80 CADASIL Subjects Progression Patterns and Implications for Clinical Trials Nils Peters, MD; Jürgen Herzog, MD; Christian Opherk, MD; Martin Dichgans, MD Background and Purpose Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small vessel disease causing stroke and dementia. The aim of this study was to explore the patterns of clinical progression in CADASIL, to check for prognostic variables, and to provide sample size estimates for future therapeutic trials. Methods Eighty CADASIL subjects (aged years [mean SD]) were followed prospectively during a mean period of months. Standardized scales on disability (Rankin), activities of daily living (Barthel index), neurological outcome (National Institutes of Health Stroke Scale [NIHSS]), and cognition (structural interview for diagnosis of Alzheimer dementia and multi-infarct dementia [SIDAM] and Mattis dementia rating scale [MDRS]) were assessed at baseline and at follow-up. Results All but 1 individual completed the protocol. At follow-up, the cohort had deteriorated with respect to all clinical scales: Rankin scores ( [mean change SD]; P 0.001), Barthel index ( ; P 0.001), NIHSS scores ( ; P 0.001), SIDAM scores ( ; P 0.004), and MDRS scores ( ; P 0.09). The spectrum ranged from marked worsening to some degree of improvement. Seventeen patients experienced a new stroke. Overall, there were 18 strokes within 173 person-years, giving an average incidence rate of stroke of 10.4 per 100 person-years (95% CI, 5.6 to 15.2). Age at baseline was found to be a predictor of clinical progression. Sample size estimates show that the number of individuals needed to include in an interventional trial (assumed duration 2 years, assumed treatment effect 40%) is 602 when using stroke occurrence as an outcome measure. Conclusions The clinical course of CADASIL includes periods of acute worsening, chronic progression, stabilization, and improvement. Sample size calculations emphasize the need for surrogate markers of disease progression for future interventional trials. (Stroke. 2004;35: ) Key Words: CADASIL longitudinal studies stroke dementia Notch Cerebral small vessel disease (SVD) is an important cause of disability and a major contributor to dementia. 1 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary variant of ischemic SVD related to mutations in the NOTCH3 gene. 2 The clinical spectrum of CADASIL has been delineated in large cross-sectional studies. 3,4 These studies have determined the frequency of manifestations such as migraine with aura (20% to 35%), recurrent ischemic episodes (70% to 85%), and cognitive deficits (50%) in mutation carriers of different ages. Yet, little is known about the patterns of disease progression and the incidence rate of acute clinical events such as strokes. Within the past few years, more than 400 families have been identified in Europe alone, and the number of newly diagnosed cases continuously increases as physicians become aware of the condition. Unfortunately, treatment options are limited. Often, antithrombotic agents such as aspirin are being used. Yet, there are no data to demonstrate efficacy of this or any other agent in CADASIL. In view of the large number of patients, controlled trials are needed. Planning such studies involves the choice of a suitable target population, decisions on outcome measures, and power calculations determining the number of cases needed to include to detect a treatment effect with sufficient power. 5 These questions are best addressed by longitudinal studies that measure the progression of clinical scales and the rate of new clinical events in a given population. Longitudinal data are further critical when looking for prognostic factors modifying disease progression. The aim of this study was (1) to obtain detailed information on the patterns of clinical progression and the annual inci- Received November 27, 2003; final revision received March 17, 2004; accepted April 2, From the Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany. The first 2 authors contributed equally to this work. Correspondence to Dr Martin Dichgans, Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, D Munich, Germany. mdichgans@nefo.med.uni-muenchen.de 2004 American Heart Association, Inc. Stroke is available at DOI: /01.STR f1 1603
2 1604 Stroke July 2004 dence rate of stroke in CADASIL, (2) to explore potential prognostic variables influencing the clinical course, and (3) to provide an estimate on the number of patients needed to include in clinical trials. Methods Subjects Study participants were selected on the basis of the following criteria: (1) aged 21 years, (2) diagnosis of CADASIL on the basis of a CADASIL-typical NOTCH3 mutation 6,7 (76 individuals) and/or a positive skin biopsy result 8,9 (53 individuals), and (3) written informed consent according to the criteria of the local ethics committee. Reasons for exclusion were a stroke within the 3 preceding months and severe interfering conditions such as malignancies. Treatment with antithrombotic agents, anticoagulants, statins, and antihypertensive drugs was allowed. Design The study protocol was approved by the local ethics committee. Patients were enrolled at the authors institution between September 1999 and October All patients were seen and examined by a trained neurologist. Patients were examined twice: at baseline and at the end of the follow-up period. At both time points, patients underwent a comprehensive protocol that included a detailed history, a complete physical and neurological examination, and neuropsychological assessment. Disability was rated according to the modified Rankin scale (a 7-point scale that assesses overall function with a strong accent on physical disability; death is rated 6), 10,11 the Barthel index (a 100-point scale that assesses activities of daily living), 12 and the National Institutes of Health Stroke Scale (NIHSS; a 12-item scale that assesses neurological deficits). 13 Neuropsychological assessment was done using the following 2 screening instruments on global cognitive functioning: the Mattis dementia rating scale (MDRS; maximum score 144) 14 and the structural interview for diagnosis of Alzheimer dementia and multi-infarct dementia (SIDAM; maximum score 55). 15 Psychiatric disturbances were assessed both at baseline and at follow up and diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Blood pressure was measured. Hypertension was defined as a systolic blood pressure 140 mm Hg, a diastolic blood pressure 90 mm Hg, or use of antihypertensive medication together with a past diagnosis of hypertension. Laboratory investigations were done at baseline and included plasma homocysteine and fibrinogen. Information of smoking, hypercholesterolemia, diabetes mellitus, and education were obtained by questionnaire. At the end of the baseline visit, patients and their proxies were instructed to carefully document new clinical events that might occur between baseline and follow-up visits. At follow-up, the authors performed a systematic inquiry regarding new clinical events within the study interval. In particular, patients were asked for the occurrence of transient ischemic attacks, strokes, cognitive worsening, migraine attacks, psychiatric disturbances, epileptic seizures, and other neurological symptoms that had occurred since baseline. They were also asked whether deficits had evolved in an acute or slowly progressive manner. Information from patients and their proxies was compared with medical records when possible. New clinical events were classified as stroke if symptoms were those of an acute stroke and at least 1 of the following 3 criteria was fulfilled: a documented new infarct on diffusionweighted images at the time of the event, a diagnosis of acute stroke made by the primary hospital, or corresponding new neurological signs at follow-up examination. Statistical Methods Statistical inferences regarding changes of clinical scores during the study interval were based on Wilcoxon tests for dependent samples. Bivariate exploration of determinants of clinical deterioration was based on Spearman rank correlation coefficients (SRCCs) and the corresponding tests. Independent variables were selected on the basis of epidemiological data suggesting a role for age, systolic blood pressure, homocysteine levels, and fibrinogen levels in SVD We also included clinical status at baseline and gender. Multivariate analysis was done using stepwise logistic regression. For this purpose, the dependent variables were dichotomized (clinical deterioration/stroke versus no deterioration/stroke). Regressors with a probability value 0.05 (Wald test) were included in the respective models. Statistical analyses were done with SPSS version for Windows (SPSS Inc) Because of the exploratory nature of this study, probability values 0.05 were regarded as significant, and no correction for multiple testing was performed. Sample Size Estimates Sample sizes were calculated according to standard methods using a validated protocol (PS program version ; available online at Calculations were done assuming a treatment effect of either 20% or 40%. These assumptions are based on results from large trials on secondary stroke prevention. 20,21 For dichotomous outcome measures (stroke occurrence and Rankin [dichotomous]), the alternative hypothesis was expressed as a relative risk (0.8 or 0.6) using an uncorrected 2 test (independent observations, prospective design). For continuous variables (clinical scores), the expected difference in population means ( ) was calculated by multiplying the observed mean change of the clinical score with a factor of 0.2 (treatment effect 20%) or 0.4 (treatment effect 40%). Results Demographic Characteristics Eighty CADASIL subjects from 56 unrelated families were included in the study. Their demographic characteristics are shown in Table 1. All but 2 subjects had developed classical manifestations of CADASIL. One patient died during the study interval, and 79 subjects completed the study. Follow-up examinations were done after a mean interval of months (range 24 to 31 months). Clinical Scales The mean clinical scores obtained in the overall cohort at baseline and at follow-up are shown in Table 2. At follow-up, all clinical scores had deteriorated when compared to baseline. Significant changes were found for the Rankin scale, the Barthel index, the NIHSS, and the SIDAM. A nonsignificant trend for deterioration was found for the MDRS. Individual longitudinal changes of disability scores (Rankin) are shown in Figure 1. Sixteen (20%) subjects deteriorated, 2 (3%) improved, and 62 (78%) remained stable. Thirteen (81%) of the patients who deteriorated had experienced a new stroke. Longitudinal changes of cognitive scores (SIDAM) are shown in Figure 2. Three (4%) subjects showed marked worsening ( 10 points), 8 (10%) subjects showed moderate worsening (6 to 10 points), and 68 (86%) subjects showed no or minor changes (0 to 5 points) of their cognitive scores. In 4 (36%) of the subjects with moderate to marked worsening of cognitive scores, onset of cognitive worsening had been acute. A SIDAM score of 33 (cut-off for dementia ) was found in 1 individual at baseline and in 7 individuals at follow-up.
3 Peters et al Follow-Up in CADASIL 1605 TABLE 1. Demographic Characteristics and Frequency of Clinical Manifestations in 80 CADASIL Subjects at Baseline Age, in years, mean SD (range) (24 64) Gender (male/female) 37/43 Body mass index, in kg/m 2, mean SD Years of education CADASIL-related symptoms Transient ischemic attack/stroke, n (%) 62 (78) Cognitive impairment, n (%) 35 (44) Migraine with aura, n (%) 27 (34) Major depression, n (%) 10 (13) Epileptic seizures, n (%) 4 (5) Vascular risk factors Hypertension, n (%) 20 (25) Hypercholesterolemia, n (%) 18 (23) Diabetes mellitus, n (%) 2 (3) Smokers, n (%) 29 (36) Homocysteine, in mol/l, mean SD (range) ( ) Fibrinogen, in mg/l, mean SD (range) ( ) Medication Taking antithrombotic medication, n (%) 60 (75) Taking anticoagulants, n (%) 1 (1) Taking antihypertensive medication, n (%) 17 (21) Taking statins, n (%) 16 (20) To assess the relationship between disability and cognitive status on a longitudinal scale, we looked at the relationship between Rankin and SIDAM scores. Longitudinal changes of the Rankin correlated with longitudinal changes of the SI- DAM (SRCC 0.43; P 0.001). This correlation remained when controlling for age at baseline (partial correlation coefficient [PCC] 0.43; P 0.001). A similar correlation was found between the NIHSS and SIDAM (PCC 0.54; P 0.001). Figure 1. Longitudinal changes of disability scores (Rankin). Each line represents 1 individual. Some individuals showed marked increases in disability, whereas others remained stable or even improved. Note that changes occurred mostly in individuals aged 40 years. New Clinical Events During Follow-Up Seventeen (22%) of the 79 subjects who completed the study experienced a new stroke. The total number of strokes was 18 and occurred within 173 person-years, which gives an average incidence rate of stroke of 10.4 per 100 person-years (95% CI 5.6 to 15.2). At follow-up, 13 (76%) of the patients with a new stroke had deteriorated with respect to their Rankin scores. In 4 (5%) cases, patients or proxies reported an acute cognitive event with marked and persistent worsening of cognitive performance. At follow-up, all of them had deteriorated with respect to their SIDAM scores ( , range 2 to 41 [mean change SD]). New clinical events are summarized in Table 3. Prognostic Factors To determine potential prognostic factors that would predict clinical worsening, we looked at the following dependent variables: changes of the Rankin score, changes of the SIDAM score, and the number of newly occurring strokes. Independent variables included age at baseline, gender, clinical status at baseline, systolic blood pressure, homocysteine level, and fibrinogen level. In bivariate correlations, age at baseline was found to be a significant predictor of clinical worsening as assessed by the Rankin scale (SRCC 0.38), the SIDAM (SRCC 0.31), and the number of new strokes (SRCC 0.36; all P 0.005). Rankin scores at baseline correlated with changes of the Rankin score during follow-up (SRCC 0.31; P 0.01). Fibrinogen levels correlated with the number of newly occurring strokes (SRCC 0.23; P 0.05), and there was a trend for a correlation with changes of the Rankin score (P 0.07). Finally, there was a trend for a correlation between systolic blood pressure and the number of new strokes (P 0.05). On multivariate analysis, age was the only significant predictor of clinical worsening as assessed by the Rankin scale (odds ratio [OR] per year, 1.10; 95% CI, 1.03 to 1.17), the SIDAM scale (OR per year, 1.07; 95% CI, 1.02 to 1.13), and the number of newly occurring strokes (OR per year, 1.10; 95% CI, 1.03 to 1.18). TABLE 2. Clinical Scales at Baseline and at Follow-Up (2 Years) Baseline Mean (SD; Range) Follow-Up Mean (SD; Range) P (Wilcoxon) Rankin score 0.7 (1.0; 0 4) 1.0 (1.5; 0 6) Barthel index 98.4 (5.0, ) 93.0 (18.7, 0 100) NIHSS score 0.9 (1.4, 0 5) 1.9 (3.4, 0 16) SIDAM score 48.1 (6.1, 19 55) 46.0 (9.8, 7 55) MDRS score (12.2, ) (23.6, ) 0.090
4 1606 Stroke July 2004 TABLE 4. Sample Size Calculations Figure 2. Longitudinal changes of cognitive scores (SIDAM). Each line represents 1 individual. Note that changes occurred mostly in individuals aged 40 years. Sample Size Estimates To explore the role of clinical outcome measures for future therapeutic trials in CADASIL, we performed sample size calculations using longitudinal data from the present study. Table 4 gives the numbers needed to include in a treatment trial, assuming a trial duration of 2 years, a power of 80%, and a type I error probability of As shown in Table 4, the number of patients was lowest when using stroke occurrence as an outcome measure and was highest when using global cognitive scores (SIDAM) as an outcome measure. Discussion This study provides prospective data on the patterns of disease progression in a large and representative cohort of CADASIL subjects. We found that the extent and mode of progression varied largely among subjects. Some patients showed a marked and rapid deterioration, whereas others remained stable or even improved. This observation reflects in part the stepwise progression that is typical of ischemic SVD. 1,22,23 In fact, most subjects with increases in disability had experienced a new stroke. Also, in some patients, onset of cognitive worsening had been acute and therefore suggestive of a strategic infarct. 1,24 26 However, we also encountered several individuals for whom deficits evolved in the absence of an acute event. In all but 4 patients with cognitive worsening, onset was insidious TABLE 3. New Clinical Events During Follow-Up (2 Years) in the 80 CADASIL Subjects Individuals (%) Stroke 17 (22) Transient ischemic attacks 15 (19) Recurrent symptoms (unclassified)* 4 (5) Acute cognitive worsening 4 (5) Attacks of migraine with aura 8 (10) Psychiatric disturbance 8 (10) Epileptic seizures 2 (3) Death 1 (1) *Recurrent symptoms such as gait disturbance that could not be classified. Included mood disorder (n 3), personality change (n 3), and other symptoms (n 4). Minimum Treatment Effect 20% (No. of Subjects Needed) Minimum Treatment Effect 40% (No. of Subjects Needed) Stroke occurrence Rankin scale (dichotomous*) Rankin scale scores Barthel index NIHSS scores SIDAM scores *Deterioration vs no deterioration. with continuous progression over several months. Also, in 2 patients, disability developed in the absence of an acute stroke. The same pattern of progression has been described in autopsy-verified cases of sporadic Binswanger s disease. 27,28 The structural correlates of this pattern (which we call chronic progressive ) are incompletely understood. Chronic progression might be related to the progression of more widespread tissue changes such as incomplete ischemic lesions and microinfarcts. However, studies correlating clinical and neuroimaging data are required to solve this issue. Our data indicate that the occurrence of disability is intimately connected to the occurrence of new strokes. In contrast, deterioration of cognitive scores was associated less strongly with acute clinical events. These findings suggest differences in the mechanisms of disability and cognitive impairment in CADASIL. Nevertheless, we found a significant correlation between cognitive scores and Rankin scores as well as NIHSS scores on a longitudinal scale that was independent of age at baseline. This finding agrees with retrospective studies in pathologically confirmed Binswanger s disease, showing that in many patients, dementia developed parallel to the occurrence of focal neurological deficits. 28 Together, these findings emphasize a close relationship between cognitive performance and physical disability in ischemic SVD. Possible structural correlates include (1) strategic lesions within regions critically involved in multiple domains such as the thalamus, and (2) a parallel progression of topographically distinct lesions. From the number of strokes that occurred within the study interval, we calculate an average incidence rate of stroke of 10.4 per 100 person-years. Molko et al followed 14 patients with MRI during a mean interval of months. 29 Two patients were mentioned to have had a new clinical event, which gives an incidence rate of 5.8 per 100 person-years. This number is somewhat lower than our estimate. Yet, the CI is large and thus fully compatible with our findings. Previous cross-sectional studies have shown that the prevalence of manifestations increases with advancing age. 3,4 The present study extends those findings by showing that age is a predictor for clinical progression. The robustness of this finding is emphasized by the fact that the ORs for clinical deterioration were almost identical for all outcome measures. We also found that Rankin scores at baseline were associated with clinical worsening during follow-up in bivariate analyses. These findings may relate to MRI findings from Molko et
5 Peters et al Follow-Up in CADASIL 1607 al, who found that the extent of tissue damage within the brain correlates with the progression of tissue changes during follow-up. 29 Together, these findings suggest an acceleration of the disease over time. The observed impact of age on clinical progression may have implications for the selection of patients in future therapeutic trials. Preventive treatments should be initiated before symptoms evolve. Yet, the inclusion of young and presymptomatic cases will enhance the number of individuals needed to document a treatment effect. Among many other aspects, this issue needs to be considered when planning a trial. Bivariate analyses also revealed a correlation between systolic blood pressure and the number of newly occurring strokes. This finding, although statistically not significant, suggests that hypertension that has been established as a main risk factor for lacunar stroke and white matter lesions 17,18 may enhance the risk of stroke in CADASIL. The observed trend for a correlation between fibrinogen levels and clinical deterioration is in line with previous studies suggesting a role for elevated fibrinogen levels as a risk factor for SVD. 16,19,30 Yet, these observations need to be confirmed in a larger study. A possible limitation of our study is the selection of symptomatic individuals and the exclusion of severely disabled patients. Also, the use of cognitive screening instruments rather than targeted neuropsychological tests (such as tests on executive function) may have resulted in a low sensitivity with regard to changes in mildly affected patients. Our sample size estimates show that the number of subjects needed to include in an interventional trial is in the range of 650 patients, provided that the assumed treatment effect is strong and dichotomous outcome variables are used. These numbers highlight the need for collaborative studies and for developing more sensitive surrogate markers of disease progression such as MRI. In fact, diffusion tensor imaging has been shown to be highly sensitive in demonstrating the progression of tissue damage even in the absence of clinical deterioration. 29 Potential MRI measures further include the volume of lesions, 31 brain atrophy rates, 32 and the number of new ischemic lesions. 33 Yet, clinical end points will set the ultimate standard for interventional trials. In the present study, the Rankin scale and the NIHSS were more sensitive than global cognitive scores in detecting changes over time. This finding suggests that global cognitive scores are less suitable as outcome measures for future interventional trials. Longitudinal studies including selected neuropsychological items known to be altered in subcortical ischemic vascular dementia 1,23 are warranted to determine the role of targeted cognitive test batteries in future interventional trials. Acknowledgments This study was supported by the Deutsche Forschungsgemeinschaft (DFG grant Di722/3 1) and Klinische Forschergruppe Molekulare Neurogenetik (KFG K1 027 and KFG K1 028). We are grateful to all the individuals who participated in this study. We appreciate the statistical support of Dr A. Crispin (Department of Medical Informatics, Biometry, and Epidemiology). We would also like to thank Dr M. Holtmannspoetter and Prof Brueckmann (Department of Neuroradiology) for performing MRIs, Dr Goehring (Institute for Clinical Chemistry) for performing the laboratory tests, Prof Müller- Höcker (Department of Pathology) for ultrastructural examination of biopsy samples, and all physicians who referred patients. References 1. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1: Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383: Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, Krebs MO, Julien J, Dubois B, Ducrocq X. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet. 1995; 346: Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J, Rungger G, Ebke M, Klockgether T, Gasser T. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44: Eng J. Sample size estimation: how many individuals should be studied? Radiology. 2003;227: Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssiere C, Cruaud C, Maciazek J, Weissenbach J, Bousser MG, Bach JF, Tournier- Lasserve E. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350: Dichgans M, Ludwig H, Müller-Höcker J, Messerschmidt A, Gasser T. Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet. 2000;8: Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol (Berl). 1995;89: Mayer M, Straube A, Bruening R, Uttner I, Pongratz D, Gasser T, Dichgans M, Müller-Höcker J. Muscle and skin biopsies are a sensitive diagnostic tool in the diagnosis of CADASIL. J Neurol. 1999;246: van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19: Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352: Mahoney FT, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14: Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25: Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, eds. Pediatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, NY: Prune and Stratton; 1977: Zaudig M, Mittelhammer J, Hiller W, Pauls A, Thora C, Morinigo A, Mombour W. SIDAM a structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-R. Psychol Med. 1991; 21: Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology. 1994;44: Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, Tyroler HA. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke. 1996;27: Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O Leary D, Fried L. Clinical correlates of white matter
6 1608 Stroke July 2004 findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27: Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian Stroke Prevention Study. J Neurol Sci. 1997;152: PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143: Caplan LR. Binswanger s disease revisited. Neurology. 1995;45: Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59: O Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol. 2003;2: Tatemichi TK, Desmond DW, Prohovnik I. Strategic infarcts in vascular dementia. A clinical and brain imaging experience. Arzneimittelforschung. 1995;45: Caplan LR, Schmahmann JD, Kase CS, Feldmann E, Baquis G, Greenberg JP, Gorelick PB, Helgason C, Hier DB. Caudate infarcts. Arch Neurol. 1990;47: Babikian V, Ropper AH. Binswanger s disease: a review. Stroke. 1987; 18: Fisher CM. Binswanger s encephalopathy: a review. J Neurol. 1989;236: Molko N, Pappata S, Mangin JF, Poupon F, LeBihan D, Bousser MG, Chabriat H. Monitoring disease progression in CADASIL with diffusion magnetic resonance imaging: a study with whole brain histogram analysis. Stroke. 2002;33: Ding J, Nieto FJ, Beauchamp NJ, Longstreth WT Jr, Manolio TA, Hetmanski JB, Fried LP. A prospective analysis of risk factors for white matter disease in the brain stem: the Cardiovascular Health Study. Neuroepidemiology. 2003;22: Dichgans M, Filippi M, Bruning R, Iannucci G, Berchtenbreiter C, Minicucci L, Uttner I, Crispin A, Ludwig H, Gasser T, Yousry TA. Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology. 1999;52: Fein G, Di Sclafani V, Tanabe J, Cardenas V, Weiner MW, Jagust WJ, Reed BR, Norman D, Schuff N, Kusdra L, Greenfield T, Chui H. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology. 2000;55: O Sullivan M, Rich PM, Barrick TR, Clark CA, Markus HS. Frequency of subclinical lacunar infarcts in ischemic leukoaraiosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Neuroradiol. 2003;24:
Diffusion Magnetic Resonance Histograms as a Surrogate Marker and Predictor of Disease Progression in CADASIL A Two-Year Follow-Up Study
Diffusion Magnetic Resonance Histograms as a Surrogate Marker and Predictor of Disease Progression in CADASIL A Two-Year Follow-Up Study Markus Holtmannspötter, MD*; Nils Peters, MD*; Christian Opherk,
More informationCerebral Microbleeds in CADASIL. A Gradient-Echo Magnetic Resonance Imaging and Autopsy Study
Cerebral Microbleeds in CADASIL A Gradient-Echo Magnetic Resonance Imaging and Autopsy Study Martin Dichgans, MD; Markus Holtmannspötter, MD; Jürgen Herzog, MD; Nils Peters, MD; Michael Bergmann, MD; Tarek
More informationMultimodal MRI in Cerebral Small Vessel Disease Its Relationship With Cognition and Sensitivity to Change Over Time
Multimodal MRI in Cerebral Small Vessel Disease Its Relationship With Cognition and Sensitivity to Change Over Time Arani Nitkunan, PhD; Tom R. Barrick, PhD; Rebecca A. Charlton, PhD; Chris A. Clark, PhD;
More informationCerebral Autosomal-Dominant Arteriopathy with Subcortical
Clinical Spectrum of CADASIL and the Effect of Cardiovascular Risk Factors on Phenotype Study in 200 Consecutively Recruited Individuals Poneh Adib-Samii, MRCP; Glen Brice, BSc; Roswell J. Martin, FRCP;
More informationDND. Phenotypic Features of Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Subjects with R544C Mutation
Print ISSN 1738-1495 / On-line ISSN 2384-0757 Dement Neurocogn Disord 2016;15(1):15-19 / http://dx.doi.org/10.12779/dnd.2016.15.1.15 ORIGINAL ARTICLE DND Phenotypic Features of Cerebral Autosomal-Dominant
More informationLacunar Infarcts Are the Main Correlate With Cognitive Dysfunction in CADASIL
Lacunar Infarcts Are the Main Correlate With Cognitive Dysfunction in CADASIL Michael K. Liem, MD; Jeroen van der Grond, PhD; Joost Haan, MD, PhD; Rivka van den Boom, MD, PhD; Michel D. Ferrari, MD, PhD;
More informationBrain Atrophy Is Related to Lacunar Lesions and Tissue Microstructural Changes in CADASIL
Brain Atrophy Is Related to Lacunar Lesions and Tissue Microstructural Changes in CADASIL Eric Jouvent, MD; Anand Viswanathan, MD, PhD; Jean-François Mangin, PhD; Mike O Sullivan, MD, PhD; Jean-Pierre
More informationCan a tissue sample help us understand a major genetic cause of stroke & vascular dementia?
stroke.org.uk Final report summary: Can a tissue sample help us understand a major genetic cause of stroke & vascular dementia? Characterising the vascular pathophysiology in CADASIL (Cerebral Autosomal
More informationCADASIL: a short review of the literature and a description of the first family from Greece
CADASIL: a short review of the literature and a description of the first family from Greece Michail Vikelis a Michail Xifaras b Dimos-Dimitrios Mitsikostas a a Department of Neurology, Athens Naval Hospital,
More informationAn Updated Systematic Review of rt-pa in Acute Ischaemic Stroke
Wardlaw An Updated Systematic Review of rt-pa in Acute Ischaemic Stroke Joanna M Wardlaw COMPETING INTERESTS The author is on the Steering Committees of the Third International Stroke Trial (IST3) and
More informationConfluent Thalamic Hyperintensities in CADASIL
Original Paper Cerebrovasc Dis 2010;30:308 313 DOI: 10.1159/000319607 Received: February 5, 2010 Accepted: May 14, 2010 Published online: July 28, 2010 Confluent Thalamic Hyperintensities in CADASIL Mathilde
More informationDepartment of Neurology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
ORIGINAL ARTICLE J Clin Neurol 2011;7:210-214 Print ISSN 1738-6586 / On-line ISSN 2005-5013 http://dx.doi.org/10.3988/jcn.2011.7.4.210 Open Access Effects of Lacunar Infarctions on Cognitive Impairment
More informationORIGINAL COMMUNICATION. Abstract Reduced cerebrovascular reactivity has been reported in patients with cerebral autosomal
J Neurol (2005) 252 : 163 167 DOI 10.1007/s00415-005-0624-3 ORIGINAL COMMUNICATION Sumeet Singhal Hugh S. Markus Cerebrovascular reactivity and dynamic autoregulation in nondemented patients with CADASIL
More informationSilent brain infarctions and high white matter grade
Hyperintensity on Cranial Magnetic Resonance Imaging A Predictor of Stroke Lewis H. Kuller, MD, DrPH; W.T. Longstreth Jr, MD, MPH; Alice M. Arnold, PhD; Charles Bernick, MD; R. Nick Bryan, MD, PhD; Norman
More informationProgression of Cerebral Small Vessel Disease in Relation to Risk Factors and Cognitive Consequences Rotterdam Scan Study
Progression of Cerebral Small Vessel Disease in Relation to Risk Factors and Cognitive Consequences Rotterdam Scan Study Ewoud J. van Dijk, MD, PhD; Niels D. Prins, MD, PhD; Henri A. Vrooman, PhD; Albert
More informationDiffusion Tensor Imaging Study of Subcortical Gray Matter in CADASIL
Diffusion Tensor Imaging Study of Subcortical Gray Matter in CADASIL N. Molko, MD; S. Pappata, MD; J.F. Mangin, PhD; C. Poupon, PhD; K. Vahedi, MD; A. Jobert, BSc; D. LeBihan, MD, PhD; M.G. Bousser, MD;
More informationMohamed Al-Khaled, MD,* Christine Matthis, MD, and J urgen Eggers, MD*
Predictors of In-hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Mohamed Al-Khaled,
More informationCerebral small vessel disease
Cerebral small vessel disease What is it? What are the clinical syndromes? How do we diagnose it? What is the pathophysiology? New insights from genetics? Possible therapies? Small Vessel disease Changes
More informationCerebral autosomal-dominant arteriopathy with subcortical
Extensive White Matter Hyperintensities May Increase Brain Volume in Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Ming Yao, MD; Eric Jouvent, MD, PhD; Marco
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationPatient with vertigo, dizziness and depression
Clinical Case - Test Yourself Neuro/Head and Neck Radiology Patient with vertigo, dizziness and depression Michael Mantatzis, Paraskevi Argyropoulou, Panos Prassopoulos Radiology Department, Democritus
More informationReliability of the Modified Rankin Scale Across Multiple Raters Benefits of a Structured Interview
Reliability of the Modified Rankin Scale Across Multiple Raters Benefits of a Structured Interview J.T. Lindsay Wilson, PhD; Asha Hareendran, PhD; Anne Hendry, FRCP; Jan Potter, FRCP; Ian Bone, MD; Keith
More informationVascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center
Vascular Dementia Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center none Disclosures Objectives To review the definition of Vascular Cognitive Impairment (VCI);
More informationCerebral white matter changes (WMCs) are frequently
Visual Rating Scales for Age-Related White Matter Changes (Leukoaraiosis) Can the Heterogeneity Be Reduced? Leonardo Pantoni, MD, PhD; Michela Simoni, MD; Giovanni Pracucci, MD; Reinhold Schmidt, MD; Frederik
More informationCharacterizing cerebral small vessel disease with a focus on CADASIL as a genetic model -an MRI based approach
Characterizing cerebral small vessel disease with a focus on CADASIL as a genetic model -an MRI based approach PhD thesis Bence Barna Gunda Semmelweis University János Szentágothai School of Neurosciences
More informationCapillary vessel wall in CADASIL angiopathy
Original article Capillary vessel wall in CADASIL angiopathy Eliza Lewandowska 1, Grażyna M. Szpak 1, Teresa Wierzba-Bobrowicz 1, Joanna Modzelewska 1, Tomasz Stępień 1, Elżbieta Pasennik 1, Bogna Schmidt-Sidor
More informationGenetic Testing of CADASIL Syndrome. Populations Interventions Comparators Outcomes Individuals: With suspected CADASIL syndrome.
Protocol Genetic Testing of CADASIL Syndrome (20475) Medical Benefit Effective Date: 04/01/18 Next Review Date: 11/18 Preauthorization Yes Review Dates: 01/12, 01/13, 01/14, 11/14, 11/15, 11/16, 11/17
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationCerebral autosomal dominant arteriopathy with subcortical. Clinical Sciences
Clinical Sciences Predictors of Clinical Worsening in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Prospective Cohort Study Hugues Chabriat, MD; Dominique
More informationThree-Dimensional MRI Analysis of Individual Volume of Lacunes in CADASIL
Three-Dimensional MRI Analysis of Individual Volume of Lacunes in CADASIL Dominique Hervé, MD; Ophélia Godin, PhD; Carole Dufouil, PhD; Anand Viswanathan, MD, PhD; Eric Jouvent, MD; Chahin Pachaï, PhD;
More informationPrior brain infarctions are commonly seen on magnetic
Prevalence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study Sarah E. Vermeer, MD; Peter J. Koudstaal, MD, PhD; Matthijs Oudkerk, MD, PhD; Albert Hofman, MD, PhD; Monique
More informationCarotid Atherosclerotic Markers in CADASIL
Original Paper DOI: 10.1159/000321932 Received: June 14, 2010 Accepted: October 8, 2010 Published online: December 21, 2010 Jérôme Mawet a Katayoun Vahedi a Mounir Aout b Eric Vicaut b Marco Duering d,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Cognitive impairment evaluated with Vascular Cognitive Impairment Harmonization Standards in a multicenter prospective stroke cohort in Korea Supplemental Methods Participants From
More informationInjuries of neural tracts in a patient with CADASIL: a diffusion tensor imaging study
Jang and Seo BMC Neurology (2015) 15:176 DOI 10.1186/s12883-015-0434-x CASE REPORT Open Access Injuries of neural tracts in a patient with CADASIL: a diffusion tensor imaging study Sung Ho Jang and You
More informationUniversity of Bristol - Explore Bristol Research
Skrobot, O. A., O'Brien, J., Black, S., Chen, C., DeCarli, C., Erkinjuntti, T.,... Kehoe, P. G. (2016). The vascular impairment of cognition classification consensus study. Alzheimer's and Dementia. DOI:
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationComparison of Different Clinical Criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the Diagnosis of Vascular Dementia
Comparison of Different Clinical Criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the Diagnosis of Vascular Dementia T. Pohjasvaara, MD, PhD; R. Mäntylä, MD; R. Ylikoski, MA; M. Kaste, MD, PhD;
More informationVague Neurological Conditions
Vague Neurological Conditions Dr. John Lefebre, MD, FRCPC Chief Regional Medical Director Europe, India, South Africa, Middle East and Turkey Canada 2014 2 3 4 Agenda Dr. John Lefebre, M.D., FRCPC 1. TIA
More informationJournal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study
Journal Club Articles for Discussion Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Engl J Med. 1995 Dec
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationdem Vascula perspective on frequency and risk factors. Last, but not least, we will consider treatment. PRACTICAL NEUROLOGY
86 PRACTICAL NEUROLOGY Vascula INTRODUCTION Vascular dementia is one of the most frequent causes of dementia in the elderly and therefore a major burden on health care systems in ageing societies. Cognitive
More informationORIGINAL CONTRIBUTION. Risk Factors for Mild Cognitive Impairment. study the Cardiovascular Health Study Cognition Study.
Risk Factors for Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 2 ORIGINAL CONTRIBUTION Oscar L. Lopez, MD; William J. Jagust; Corinne Dulberg, PhD; James T. Becker,
More informationTurkish Title: Akut Eş Zamanlı Subkortikal Infarktların Neden Olduğu Progresif Bulber Paralizi ile Prezente olan CADASIL Olgusu
DOI: Manuscript Type: Case Report Turkish Title: Akut Eş Zamanlı Subkortikal Infarktların Neden Olduğu Progresif Bulber Paralizi ile Prezente olan CADASIL Olgusu Turkish Running Head: Eş Zamanlı İnfartlarla
More informationSupplementary Note. Patient #1 Additional Details
Supplementary Note Patient #1 Additional Details Past medical history: The patient was ambidextrous. She had a history of hypertension, hyperlipidemia, migraines, and remote history of an ANA-positive
More informationThrombolytic Therapy in Clinical Practice The Norwegian Experience
Thrombolytic Therapy in Clinical Practice The Norwegian Experience Thomassen Lars Thomassen, Ulrike Waje-Andreassen, Halvor Næss ABSTRACT Background: Awaiting the European approval of thrombolysis, we
More informationW hite matter high intensity lesions (WML) on T2
576 PAPER Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis H Yamauchi, H Fukuda, C Oyanagi... See end of article for authors affiliations... Correspondence
More informationNoncontrast computed tomography (CT) reliably distinguishes
Extent of Early Ischemic Changes on Computed Tomography (CT) Before Thrombolysis Prognostic Value of the Alberta Stroke Program Early CT Score in ECASS II Imanuel Dzialowski, MD; Michael D. Hill, MD, MSc,
More informationSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Original Article Medical Journal of the Islamic Republic of Iran, Vol. 27, No. 3, Aug 2013, pp. 113-118 Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationMagnetic resonance imaging (MRI) has the potential to
Frequency and Location of Microbleeds in Patients With Primary Intracerebral Hemorrhage Gudrun Roob, MD; Anita Lechner, MD; Reinhold Schmidt, MD; Erich Flooh, MSc; Hans-Peter Hartung, MD; Franz Fazekas,
More informationVisual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging
Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging Scale Comparison, Interrater Agreement, and Correlations With Quantitative Measurements P. Kapeller, MD; R. Barber, MD; R.
More informationTime to treatment is a critical factor in the outcome of
Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale Maarten G. Lansberg,
More informationThe Effect of Statin Therapy on Risk of Intracranial Hemorrhage
The Effect of Statin Therapy on Risk of Intracranial Hemorrhage JENNIFER HANIFY, PHARM.D. PGY2 CRITICAL CARE RESIDENT UF HEALTH JACKSONVILLE JANUARY 23 RD 2016 Objectives Review benefits of statin therapy
More informationUniversity of Bristol - Explore Bristol Research
Skrobot, O., Black, S., Chen, C., Decarli, C., Erkinjuntti, T., Ford, G. A.,... Kehoe, P. G. (07). Progress towards standardised diagnosis of vascular cognitive impairment: Guidelines from the Vascular
More informationAcute Stroke Care: the Nuts and Bolts of it. ECASS I and II ATLANTIS. Chris V. Fanale, MD Colorado Neurological Institute Swedish Medical Center
Acute Stroke Care: the Nuts and Bolts of it Chris V. Fanale, MD Colorado Neurological Institute Swedish Medical Center ECASS I and II tpa for patients presenting
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationUNIVERSITY OF WESTERN ONTARIO
UNIVERSITY OF WESTERN ONTARIO Vladimir Hachinski, CM, MD, FRCPC, DSc Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada Vladimir.hachinski@lhsc.on.ca ALZHEIMER
More informationDiagnosing vascular cognitive impairment and dementia: concepts and controversies
SECTION 1 Diagnosis 1 Diagnosing vascular cognitive impairment and dementia: concepts and controversies Timo Erkinjuntti and Serge Gauthier Introduction Vascular cognitive impairment, the recent modification
More informationCerebral autosomal-dominant arteriopathy with subcortical
Insidious Cognitive Decline in CADASIL Kaarina Amberla, MSc; Minna Wäljas, MSc; Susanna Tuominen, MD; Ove Almkvist, PhD; Minna Pöyhönen, MD; Seppo Tuisku, MD; Hannu Kalimo, MD; Matti Viitanen, MD Background
More informationCADASIL: structural MR imaging changes and apolipoprotein E genotype S E V E N
CADASIL: structural MR imaging changes and apolipoprotein E genotype S E V E N CADASIL: structural MR imaging changes and apolipoprotein E genotype R. van den Boom S.A.J. Lesnik Oberstein A.A. van den
More informationThe comparisons of phenotype and genotype between CADASIL and CADASILlike patients and population-specific evaluation of CADASIL scale in China
He et al. The Journal of Headache and Pain (2016) 17:55 DOI 10.1186/s10194-016-0646-5 The Journal of Headache and Pain RESEARCH ARTICLE Open Access The comparisons of phenotype and genotype between CADASIL
More informationBrain tissue and white matter lesion volume analysis in diabetes mellitus type 2
Brain tissue and white matter lesion volume analysis in diabetes mellitus type 2 C. Jongen J. van der Grond L.J. Kappelle G.J. Biessels M.A. Viergever J.P.W. Pluim On behalf of the Utrecht Diabetic Encephalopathy
More informationAortic Atherosclerosis at Middle Age Predicts Cerebral White Matter Lesions in the Elderly
Aortic Atherosclerosis at Middle Age Predicts Cerebral White Matter Lesions in the Elderly Frank-Erik de Leeuw, MD, PhD; Jan Cees de Groot, MD, PhD; Matthijs Oudkerk, MD, PhD; Jacqueline C.M. Witteman,
More information2002 CADASIL Newsletters The unofficial CADASIL newsletter Issue VIIII - June 2002
2002-2003 NEWSLETTERS 2002 CADASIL Newsletters The unofficial CADASIL newsletter Issue VIIII - June 2002 CADASIL - Cerebral Autosomal dominant arteriopathy with sub cortical infarctions and Leukoencephalopathy
More informationDefinition พ.ญ.ส ธ ดา เย นจ นทร. Epidemiology. Definition 5/25/2016. Seizures after stroke Can we predict? Poststroke seizure
Seizures after stroke Can we predict? พ.ญ.ส ธ ดา เย นจ นทร PMK Epilepsy Annual Meeting 2016 Definition Poststroke seizure : single or multiple convulsive episode(s) after stroke and thought to be related
More informationChapter 11 summary definitief ineke brands.indd :57:59
chapter 11 Summary chapter 11 Both type 1 and type 2 diabetes mellitus are associated with altered brain function, a complication referred to as diabetic encephalopathy. Previous studies have shown that
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationNeuropathological Correlates of Temporal Pole White Matter Hyperintensities in CADASIL
Neuropathological Correlates of Temporal Pole White Matter Hyperintensities in CADASIL Yumi Yamamoto, MRes; Masafumi Ihara, MD; Carina Tham, MRes; Roger W.C. Low, PhD; Janet Y. Slade, BSc; Tim Moss, FRCPath;
More informationMagnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
More informationThe influence of genetic and cardiovascular risk factors on the CADASIL phenotype
Brain Advance Access published June 30, 2004 DOI: 10.1093/brain/awh223 Brain Page 1 of 8 The influence of genetic and cardiovascular risk factors on the CADASIL phenotype Sumeet Singhal, 1 Steve Bevan,
More informationPREDICTION OF GOOD FUNCTIONAL RECOVERY AFTER STROKE BASED ON COMBINED MOTOR AND SOMATOSENSORY EVOKED POTENTIAL FINDINGS
J Rehabil Med 2010; 42: 16 20 ORIGINAL REPORT PREDICTION OF GOOD FUNCTIONAL RECOVERY AFTER STROKE BASED ON COMBINED MOTOR AND SOMATOSENSORY EVOKED POTENTIAL FINDINGS Sang Yoon Lee, MD 1, Jong Youb Lim,
More informationCerebral Hemodynamics in CADASIL Before and After Acetazolamide Challenge Assessed With MRI Bolus Tracking
Cerebral Hemodynamics in CADASIL Before and After Acetazolamide Challenge Assessed With MRI Bolus Tracking H. Chabriat, MD, PhD; S. Pappata, MD; L. Ostergaard, PhD; C.A. Clark, PhD; M. Pachot-Clouard,
More informationORIGINAL CONTRIBUTION. How Complex Interactions of Ischemic Brain Infarcts, White Matter Lesions, and Atrophy Relate to Poststroke Dementia
ORIGINAL CONTRIBUTION How Complex Interactions of Ischemic Brain Infarcts, White Matter Lesions, and Atrophy Relate to Poststroke Dementia Tarja Pohjasvaara, MD, PhD; Riitta Mäntylä, MD; Oili Salonen,
More informationPRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans
PRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans Inclusion Criteria Clinical syndrome Patients must have clinical evidence
More informationEmergency Department Management of Acute Ischemic Stroke
Emergency Department Management of Acute Ischemic Stroke R. Jason Thurman, MD Associate Professor of Emergency Medicine and Neurosurgery Associate Director, Vanderbilt Stroke Center Vanderbilt University,
More informationClinic-based study of family history of vascular risk factors and migraine
J Headache Pain (2005) 6:412 416 DOI 10.1007/s10194-005-0239-1 BRIEF REPORT Grace Yoon Susan Baggaley Peter Bacchetti Ying-Hui Fu Kathleen B. Digre Louis J. Ptacek Clinic-based study of family history
More informationJudicious use of thrombolytic agents has greatly improved the
Predictors of Clinical Improvement, Angiographic Recanalization, and Intracranial Hemorrhage After Intra-Arterial Thrombolysis for Acute Ischemic Stroke J.I. Suarez, MD; J.L. Sunshine, MD; R. Tarr, MD;
More informationBlood Pressure Variability and Hemorrhagic Transformation after Intravenous Thrombolysis in Acute Ischemic Stroke
www.jneurology.com Neuromedicine www.jneurology.com Research Article Open Access Blood Pressure Variability and Hemorrhagic Transformation after Intravenous Thrombolysis in Acute Ischemic Stroke Hanna
More informationHYPERTENSIVE ENCEPHALOPATHY
HYPERTENSIVE ENCEPHALOPATHY Reversible posterior leukoencephalopathy syndrome Cause Renal disease Pheochromocytoma Disseminated vasculitis Eclampsia Acute toxemia Medications & illicit drugs (cocaine)
More informationCerebral autosomal dominant arteriopathy with subcortical
Cardiac Autonomic Nervous System and Risk of Arrhythmias in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Alessandra Rufa, MD; Francesca Guideri,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/42751 holds various files of this Leiden University dissertation Author: Foster-Dingley, J.C. Title: Blood pressure in old age : exploring the relation
More informationTopical Review. Section Editor: Marc Fisher, MD. Progression of Leukoaraiosis and Cognition
Topical Review Section Editor: Marc Fisher, MD Progression of Leukoaraiosis and Cognition Reinhold Schmidt, MD; Katja Petrovic, PhD; Stefan Ropele, PhD; Christian Enzinger, MD; Franz Fazekas, MD Background
More informationThe secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy,
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. LEASURE, MD Results of the Management of Atherothrombosis With Clopidogrel in High-Risk atients Trial Implications for the Neurologist Marc Fisher, MD The secondary
More informationGenotype Phenotype relation in portuguese patients with NOTCH3 mutation
2013/2014 Tiago Augusto Paiva de Magalhães Genotype Phenotype relation in portuguese patients with NOTCH3 mutation março, 2014 Tiago Augusto Paiva de Magalhães Genotype Phenotype relation in portuguese
More informationArticle ID: WMC ISSN
Article ID: WMC004795 ISSN 2046-1690 Correlation of Alberta Stroke Program Early Computed Tomography Score on CT and Volume on Diffusion Weighted MRI with National Institutes of Health Stroke Scale Peer
More informationPresence and severity of carotid siphon calcification on computed tomography images in mild cognitive impairment
Presence and severity of carotid siphon calcification on computed tomography images in mild cognitive impairment Poster No.: C-2117 Congress: ECR 2013 Type: Scientific Exhibit Authors: S. Rutkauskas, S.
More informationFILE / PERIVENTRICULAR MICROVASCULAR ISCHEMIC CHANGES EBOOK
07 June, 2018 FILE / PERIVENTRICULAR MICROVASCULAR ISCHEMIC CHANGES EBOOK Document Filetype: PDF 365.11 KB 0 FILE / PERIVENTRICULAR MICROVASCULAR ISCHEMIC CHANGES EBOOK I recently had a MRI last week with
More informationNeurological Deterioration in Acute Ischemic Stroke
Neurological Deterioration in Acute Ischemic Stroke Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) I A. Dávalos, MD; D. Toni, MD; F. Iweins, MSc; E.
More informationGenetic Testing for CADASIL Syndrome
Medical Policy Manual Genetic Testing, Policy No. 51 Genetic Testing for CADASIL Syndrome Next Review: April 2019 Last Review: May 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are developed
More informationWORKING MEMORY FUNCTIONS AT PRESTROKE STAGE OF CADASIL. Tampere, Finland
WORKING MEMORY FUNCTIONS AT PRESTROKE STAGE OF CADASIL Minna Wäljas 1,2, Seppo Tuisku 3, and Jari K. Hietanen 1 1 Human Information Processing Laboratory, Department of Psychology, University of Tampere,
More informationENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist
ENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist Pharmacy Grand Rounds 26 July 2016 2015 MFMER slide-1 Learning
More informationKing s Research Portal
King s Research Portal DOI: 10.1111/j.1747-4949.2011.00763.x Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Brookes, R.
More informationPhenotype of a Homozygous CADASIL Patient in Comparison to 9 Age-Matched Heterozygous Patients With the Same R133C Notch3 Mutation
Phenotype of a Homozygous CADASIL Patient in Comparison to 9 Age-Matched Heterozygous Patients With the Same R133C Notch3 Mutation Susanna Tuominen, MD; Vesa Juvonen, MSc; Kaarina Amberla, MSc; Tapani
More informationCommon Versus Uncommon Causes of Dementia
Edith Cowan University Research Online ECU Publications Pre. 2011 2005 Common Versus Uncommon Causes of Dementia Nicola Lautenschlager University of Western Australia Ralph Martins Edith Cowan University
More informationPost-stroke cognitive impairment is common even after successful clinical recovery
ORIGINAL ARTICLE Post-stroke cognitive impairment is common even after successful clinical recovery H. Jokinen, S. Melkas, R. Ylikoski, T. Pohjasvaara, M. Kaste, T. Erkinjuntti and M. Hietanen Clinical
More informationSmall Vessel Disease and Dementia:
KDA Programme lecture October 2005 Small Vessel Disease and Dementia: Prof Raj N Kalaria FRCP University of Newcastle upon Tyne Wolfson Research Centre Newcastle General Hospital United Kingdom Email:
More informationMRI of Pathological Aging Brain
MRI of Pathological Aging Brain Yukio Miki Department of Radiology, Osaka City University A variety of pathological changes occur in the brain with aging, and many of these changes can be identified by
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More information